CCR 20th anniversary commentary: In the beginning, there was PS-341.
Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708).
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland. Beverly.Teicher@nih.gov teicherba@mail.nih.gov.
Beverly A
BA
Teicher
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Kenneth C
KC
Anderson
D000970:Antineoplastic Agents / Q000266:history; D000069286:Bortezomib / Q000266:history / Q000627:therapeutic use; D049673:History, 20th Century; D049674:History, 21st Century; D061988:Proteasome Inhibitors / Q000266:history / Q000627:therapeutic use
D000970:Antineoplastic Agents; D061988:Proteasome Inhibitors; D000069286:Bortezomib